Human Health
Pipeline
Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we continue our track record of long-term innovation-led performance.
Note: This webpage hosts content for general public as well as for healthcare professional and journalists & media professionals. To be able to see and access respective content you need to select your profession through the filter button on the right.
-
Human Pharma Pipeline
Pipeline
This represents a selection of assets in our research and development portfolio in September 2020.
-
PRESS RELEASE
Boehringer Ingelheim begins a phase 2 clinical trial of a targeted therapy to help people with severe respiratory illness from COVID-19